Switching from Combination Tablet to Separate Medications
Replace Xigduo XR 5-1000 (dapagliflozin 5mg/metformin 1000mg once daily) with separate dapagliflozin 5mg once daily plus metformin extended-release 1000mg once daily, both taken together in the morning with food.
Direct Conversion Strategy
The FDA label data demonstrates bioequivalence between the fixed-dose combination and separate component tablets 1. This means you can directly substitute:
- Dapagliflozin 5mg tablet (once daily)
- Metformin XR 1000mg tablet (once daily)
Both should be taken simultaneously in the morning with a meal to maintain the same pharmacokinetic profile as the combination product.
Key Clinical Evidence
The bioequivalence has been rigorously established across multiple populations 2, 3, 4:
- The 90% confidence intervals for AUC and Cmax fall within 80-125% bioequivalence limits
- Plasma concentration-time profiles are nearly superimposable between fixed-dose combination and separate tablets
- No clinically meaningful differences in glycemic control, with identical HbA1c reductions of approximately 0.5-0.7% when added to existing therapy
Practical Implementation
Timing: Administer both tablets together once daily in the morning with food. Food intake is important as it:
- Reduces gastrointestinal side effects from metformin
- Maintains consistent absorption patterns established in bioequivalence studies 4
Dosing considerations:
- If the patient was on Xigduo XR 5-1000, prescribe dapagliflozin 5mg + metformin XR 1000mg
- If they were on Xigduo XR 10-1000, prescribe dapagliflozin 10mg + metformin XR 1000mg
- Metformin XR can be given as a single 1000mg tablet or two 500mg tablets (bioequivalent) 1
Important Caveats
Pill burden: While bioequivalence is established, taking two separate tablets instead of one may reduce adherence 5, 6. Monitor compliance closely during the first 3 months after switching.
No dose adjustment needed: The separate components provide identical systemic exposure to the combination tablet, so no titration or dose modification is required 2, 3.
Renal function: Ensure eGFR ≥30 mL/min/1.73m² before continuing metformin 7. Both medications should be used cautiously if eGFR falls below this threshold.
Gastrointestinal tolerance: If the patient experiences increased GI symptoms after switching, this likely reflects nocebo effect or timing changes rather than true pharmacologic differences, as the metformin formulation (extended-release) remains the same 7.